Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial

Auteurs

S. Dent, J. Cortés, Y.-H. Im, V. Diéras, N. Harbeck, I.E. Krop, T.R. Wilson, N. Cui, F. Schimmoller, J.Y. Hsu, J. He, M. De Laurentiis, S. Sousa, P. Drullinsky, W. Jacot